Friday, December 3, 2021
Shares of Unichem Laboratories surged 15 per cent to Rs 257 on the BSE in Friday’s intra-day trade after Unichem Laboratories has received ANDA approval for its Aripiprazole Tablets USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Abilify Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Otsuka Pharmaceutical Company. Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder. The product will be commercialized from Unichem’s Ghaziabad Plant, the company said. The company reported a consolidated net loss of Rs 12.82 crore in Q2 FY22 as compared to a net profit of Rs 8.74 crore in Q2 FY21. Net sales during the quarter decreased 8.5% Y-o-Y (year-on-year) to Rs 290.66 crore.
